TABLE 1.
Characteristics of NSCLC patients with brain metastasis
| Characteristics | Total | The number of involved extracranial organs | p value | |||
|---|---|---|---|---|---|---|
| 0 | 1 | 2 | ≥3 | |||
| 5974 (100%) | 2750 (46.03%) | 1933 (32.36%) | 970 (16.24%) | 321 (5.37%) | ||
| Histopathology | <0.001 | |||||
| Adenocarcinoma | 4519 (75.64%) | 1997 (72.62%) | 1500 (77.60%) | 767 (79.07%) | 255 (79.44%) | |
| Squamous cell carcinoma | 898 (15.03%) | 471 (17.13%) | 161 (13.50%) | 127 (13.09%) | 39 (12.15%) | |
| Large cell carcinoma | 209 (3.50%) | 119 (4.33%) | 61 (3.16%) | 20 (2.06%) | 9 (2.80%) | |
| Other | 348 (5.83%) | 163 (5.93%) | 111 (5.74%) | 56 (5.77%) | 18 (5.61%) | |
| Age | 0.288 | |||||
| 21–49 | 541 (9.06%) | 245 (8.87%) | 162 (8.38%) | 99 (10.21%) | 36 (11.21%) | |
| 50–59 | 1675 (28.04%) | 1675 (0.27%) | 550 (28.45%) | 278 (28.66%) | 97 (30.22%) | |
| ≥60 | 3758 (62.91%) | 3758 (63.85%) | 1221 (63.17%) | 593 (61.13%) | 188 (58.57%) | |
| Race | <0.001 | |||||
| White | 4619 (77.32%) | 2168 (78.84%) | 1484 (76.77%) | 732 (75.46%) | 235 (73.21%) | |
| Black | 771 (12.91%) | 371 (13.49%) | 252 (13.04%) | 112 (11.55%) | 36 (11.21%) | |
| Other a | 584 (9.78%) | 211 (7.67%) | 197 (10.19%) | 126 (12.99%) | 50 (15.58%) | |
| Gender | 0.685 | |||||
| Male | 2910 (48.71%) | 132 (48.33%) | 937 (48.47%) | 478 (49.28%) | 166 (51.71%) | |
| Female | 3064 (51.29%) | 142 (51.67%) | 996 (51.53%) | 492 (50.72%) | 155 (48.29%) | |
| Marital status | 0.01 | |||||
| Married | 2572 (43.05%) | 1261 (45.85%) | 790 (40.87%) | 389 (40.10%) | 132 (41.12%) | |
| Unmarried | 3179 (53.21%) | 139 (50.62%) | 1066 (55.15%) | 545 (56.19%) | 176 (54.83%) | |
| Unknown | 223 (3.73%) | 97 (3.53%) | 77 (3.98%) | 36 (3.71%) | 13 (4.05%) | |
| Differentiation | 0.259 | |||||
| Well | 139 (2.33%) | 56 (2.04%) | 50 (2.59%) | 25 (2.58%) | 8 (2.49%) | |
| Moderately | 796 (13.32%) | 382 (13.89%) | 264 (13.66%) | 117 (12.06%) | 33 (10.28%) | |
| Poorly | 1760 (29.46%) | 907 (32.98%) | 547 (28.30%) | 241 (24.85%) | 65 (20.25%) | |
| Undifferentiated | 86 (1.44%) | 50 (1.82%) | 23 (1.19%) | 10 (1.03%) | 3 (0.93%) | |
| Unknown | 3193 (53.45%) | 1355 (49.27%) | 1049 (54.27%) | 577 (9.48%) | 212 (66.04%) | |
| T Stage | <0.001 | |||||
| T1 | 743 (12.44%) | 455 (16.55%) | 207 (10.71%) | 75 (7.73%) | 6 (1.87%) | |
| T2 | 1765 (29.54%) | 1023 (37.20%) | 524 (27.11%) | 184 (18.97%) | 34 (10.59%) | |
| T3 | 1541 (25.80%) | 628 (22.84%) | 530 (27.42%) | 290 (29.90%) | 93 (28.97%) | |
| T4 | 1925 (32.22%) | 644 (23.42%) | 672 (34.76%) | 421 (43.40%) | 188 (58.57%) | |
| N Stage | <0.001 | |||||
| N0 | 1301 (21.78%) | 775 (28.18%) | 355 (18.37%) | 140 (14.43%) | 31 (9.66%) | |
| N1 | 520 (8.70%) | 276 (10.04%) | 154 (7.97%) | 70 (7.22%) | 20 (6.23%) | |
| N2 | 2829 (47.36%) | 127 (46.18%) | 942 (48.73%) | 470 (48.45%) | 147 (45.79%) | |
| N3 | 1183 (19.80%) | 372 (13.53%) | 434 (22.45%) | 263 (27.11%) | 114 (35.51%) | |
| Unknown | 141 (2.36%) | 57 (2.07%) | 48 (2.48%) | 27 (2.78%) | 9 (2.80%) | |
| Surgery | <0.001 | |||||
| Yes | 135 (1.96%) | 86 (3.13%) | 24 (1.24%) | 5 (0.52%) | 2 (0.62%) | |
| No | 5839 (98.04%) | 2664 (96.87%) | 1909 (98.76%) | 965 (99.48%) | 319 (99.38%) | |
| Radiation therapy | 0.609 | |||||
| Yes | 5857 (97.74%) | 2689 (97.78%) | 1886 (97.57%) | 947 (97.63%) | 317 (98.75%) | |
| No | 117 (2.26%) | 61 (2.22%) | 47 (2.43%) | 23 (2.37%) | 4 (1.25%) | |
| Chemotherapy | 0.768 | |||||
| Yes | 3749 (62.76%) | 1707 (62.07%) | 1229 (63.58%) | 611 (62.99%) | 202 (62.93%) | |
| No | 2225 (37.24%) | 1043 (37.93%) | 704 (36.42%) | 359 (37.01%) | 119 (37.07%) | |
Abbreviations: NSCLC, non‐small cell lung cancer.
a
American Indian/AK Native, Asian/Pacific Islander (in bold).